経皮パッチの世界市場：市場の機会、パッチ用量、価格、臨床試験動向（2030年）

世界の経皮パッチの市場規模は、2030年までに180億米ドルになると予測されています。現在、米国が世界の経皮パッチ市場を独占し、規模は40億米ドル以上となっています。2030年までに中国が経皮パッチの成長市場に浮上するとみられています。

世界の経皮パッチ市場は、ダイナミックで激しい競争の場へと急速に変貌を遂げており、新興企業も既存企業も患者の増大する需要に対応するために絶え間ない技術革新を行っています。これらのパッチは、皮膚を通して治療薬の制御された安定した放出を促進し、疼痛管理、禁煙、ホルモン補充療法など、多様な病状に対応しています。その成功の顕著な例は、2000年代初頭に禁煙補助薬として人気を博したニコチンパッチです。それ以来、経皮パッチによって治療される症状の範囲はかなり広がり、現在ではADHD、ホルモン欠乏症、吐き気などの治療が含まれるようになっています。経皮パッチは従来のドラッグデリバリー法に比べて高価な傾向があるが、その有利な安全性と有効性プロファイルに後押しされ、一貫して市場の成長が促進されています。

世界の経皮パッチ市場の拡大には、規制当局の承認取得が不可欠です。規制当局からの承認取得は、経皮パッチのドラッグデリバリーとしての信頼性を確認する上で極めて重要です。例えば、Zydus Lifesciencesは2024年8月、吐き気や嘔吐の治療を目的としたスコポラミン経皮吸収システムの最終承認をFDAから取得しました。同様に、Sino Biopharmaceuticalは、軽度から中等度のアルツハイマー病治療を目的としたリバスチグミン経皮吸収パッチ製剤のNMPA承認を2024年9月に取得しました。この承認は、中国で販売許可された初の国産リバスチグミン貼付剤であり、経皮吸収型貼付剤が世界の規模で受け入れられつつあることを示す重要な成果です。

経皮パッチの商業的可能性は、ドラッグ・デリバリー・システムにおける継続的な技術革新によって、さらに大きく向上しています。例えば、Anodyne NanotechのHeroPatch（TM）プラットフォームは、セマグルチドを含むGLP-1受容体作動薬の経皮投与において、50％以上のバイオアベイラビリティを達成し、有望な前臨床試験結果を実証しています。この進歩は、従来の注射に代わる、針を使わない週1回の投与方法を提供することにより、糖尿病などの慢性疾患の管理を一変させる可能性があります。ヒーローパッチ（TM）の臨床試験は2025年に開始される予定であり、ドラッグデリバリー技術における極めて重要な要素としての経皮パッチの役割が強化されることになります。

現在、複数の経皮パッチが臨床試験中であり、ドラッグデリバリーにおけるこの方法の大きな可能性を強調しています。これらのパッチは、慢性疼痛管理、糖尿病治療、さらにはワクチン接種など、さまざまな治療分野で研究が進められています。すでに70近い経皮吸収パッチが世界の承認を得ており、市場の成長軌道は力強いものと思われます。皮膚刺激や、1枚のパッチで高用量の薬物を送達することの限界など、課題は残っているもの、研究者たちはこれらの問題への対処を進めています。経皮パッチの展望は有望であり、薬剤処方、パッチデザイン、患者のアドヒアランスの継続的な向上が市場成長をさらに促進すると予想されます。

当レポートは、世界の経皮パッチ市場について調査し、市場の概要とともに、薬剤動向、臨床試験動向、地域別動向、および市場に参入する企業の競合情勢などを提供しています。

目次

第1章 経皮パッチのイントロダクション

第2章 経皮吸収パッチの分類

• 接着剤中の単層/多層薬剤
• リザーバー経皮パッチ
• マトリックスベースの経皮パッチ
• 蒸気パッチ
• アクティブおよびパッシブパッチ

第3章 経皮パッチ別ドラッグデリバリーのメカニズム

• 経皮治療薬の特性
• 経皮パッチの成分
• 乗り物酔いのメカニズム、ニコチン、女性用経皮避妊薬パッチ
• 経皮パッチと従来のドラッグデリバリー方法の比較

第4章 世界の経皮パッチ市場の展望

• 現在の市場シナリオ
• 将来の市場機会

第5章 地域別の世界の経皮パッチ市場の動向

• 米国
• 欧州
• 中国
• 日本
• 韓国
• 英国

第6章 企業別、適応症別、相別の世界パッチ臨床パイプライン

• 研究
• 前臨床
• 第I相
• 第I/II相
• 第II相
• 第III相
• 事前登録
• 登録済み

第7章 世界的に販売されている経皮吸収パッチの臨床的洞察

第8章 心血管疾患用経皮パッチ- 市場での入手可能性、投与量、価格分析

• ニトログリセリン経皮パッチ
• クロニジン経皮パッチ
• ビソプロロール経皮パッチ（ビソノ）

第9章 経皮鎮痛パッチ- 市場での入手可能性、投与量、価格分析

• フェンタニル経皮パッチ
• ブプレノルフィン経皮パッチ
• ジクロフェナク経皮パッチ
• ケトプロフェン経皮パッチ（Mohrus）
• リドカイン経皮パッチ
• カプサイシン経皮パッチ（Qutenza）
• メチルサリケート経皮パッチ
• グリコールサリチル酸経皮吸収型貼付剤（Tokuhon E）
• フルルビプロフェン経皮パッチ

第10章 ホルモン療法における経皮パッチ- 市場での入手可能性、投与量、価格分析

• エストラジオール経皮パッチ
• テストステロン経皮パッチ（Androderm）
• エストラジオール/ノルエチステロン経皮パッチ
• エストラジオール/レボノルゲストレル経皮パッチ
• エチニルエストラジオール/レボノルゲストレル（Twirla）
• エチニルエストラジオール/ゲストデン（Apleek）

第11章 神経疾患用経皮パッチ- 市場での入手可能性、投与量、価格分析

• スコポラミン経皮パッチ（Transderm-Scop）
• セレギリン経皮パッチ（Emsam）
• メチルフェニデート経皮パッチ（Daytrana）
• デキストロアンフェタミン経皮パッチ（Xelstrym）
• ブロナンセリン経皮パッチ（Lonasen）
• アセナピン経皮パッチ（Secuado）
• リバスチグミン経皮パッチ
• ロチゴチン経皮パッチ（Neupro）
• 塩酸ロピニロール（Haruropi Tape）
• ドネペジル経皮パッチ（Adlarity）

第12章 その他の症状に対するパッチ- 市場での入手可能性、投与量、価格分析

• ニコチン経皮パッチ（Nicoderm CQ/Nicotinell TTS）
• オキシブチニン経皮パッチ（Oxytrol/Kentera）
• グラニセトロン経皮パッチ（Sancuso）
• エメダスチン経皮パッチ（Allesaga）
• フィブリンシーラント経皮パッチ
• 5-アミノレブリン酸経皮パッチ（Alacare）
• ツロブテロール経皮パッチ

第13章 世界の経皮パッチ市場力学

第14章 競合情勢

• AbbVie
• Bayer HealthCare Pharmaceuticals
• Corium International
• Endo Pharmaceuticals
• Hisamitsu Pharmaceutical
• Luye Pharma
• Noven Pharmaceuticals
• Novartis
• Purdue Pharma
• Scilex Pharmaceuticals
• Searchlight Pharma
• Somerset Pharmaceuticals
• Teikoku Seiyaku
• Teva Pharmaceuticals
• UCB
• DURECT Corporation
• Senju Pharmaceutical

List of Figures

• Figure 1-1: Transdermal Permeation - Steps Involved
• Figure 1-2: Transdermal Patch - Ideal Properties
• Figure 2-1: Commercially Available Transdermal Patch Types
• Figure 2-2: Multilayer Transdermal Patch
• Figure 2-3: Reservoir Transdermal Patch System
• Figure 2-4: Matrix Based Transdermal Patches
• Figure 3-1: Transdermal Therapeutics - Properties
• Figure 3-2: Transdermal Patch - Components
• Figure 3-3: Permeation Enhancer - Types
• Figure 3-4: Iontophoresis - Schematic Representation
• Figure 3-5: Scopolamine Transdermal Patch - Mechanism
• Figure 3-6: Nicotine Transdermal Patch - Mechanism
• Figure 3-7: Female Contraceptive Transdermal Patch - Mechanism
• Figure 3-8: Traditional Drug Delivery Methods - Challenges
• Figure 3-9: Transdermal Patch - Advantages
• Figure 3-10: Consistent Drug Supply By Transdermal Patch
• Figure 4-1: Global - Transdermal Patch Market Size (US$ Billion), 2024 - 2030
• Figure 4-2: Global Transdermal Patch Market By Region (US$ Billion), 2024
• Figure 4-3: Global Transdermal Patch Market By Region (%), 2024
• Figure 4-4: Global Transdermal Patch Market By Region (US$ Billion), 2030
• Figure 4-5: Global Transdermal Patch Market By Region (%), 2030
• Figure 8-1: Nitro-Dur - Price Per Unit & Supply Of Transdermal Films (US$), March'2025
• Figure 8-2: Nitro TD Patch A - Price Per Unit & Supply Of Transdermal Films (US$), February'2025
• Figure 8-3: Generic Nitroglycerin Transdermal Patch - Price Per Unit & Supply (US$), February'2025
• Figure 8-4: Catapres-TTS - FDA Approval & First Generic Approval Year
• Figure 8-5: Catapres-TTS - Price Per Unit & Supply (US$), February'2025
• Figure 8-6: Catapres-TTS Transdermal Patch - Recommended Initial & Incremented Dose (mg/Week)
• Figure 8-7: Generic Clonidine Transdermal Patch - Price Per Unit & Supply (US$), February'2025
• Figure 8-8: Bisono - Approval Year By Indication
• Figure 8-9: Bisono - Price Per Unit By Dose (US$), February'2025
• Figure 8-10: Bisono - Initial & Maximum Recommended Dose (mg/hr)
• Figure 9-1: Duragesic - Approval Year By Region
• Figure 9-2: Durotep MT - Price Per Unit By Dose (US$), February'2025
• Figure 9-3: OneDuro - Price Per Unit By Dose (US$), February'2025
• Figure 9-4: Generic Fentanyl Transdermal Patch - Price Per Unit & Supply In US (US$), March'2025
• Figure 9-5: Fentos - Price Per Unit By Dose (US$), February'2025
• Figure 9-6: Fentos - Annual Sales (US$), 2020-2024
• Figure 9-7: Generic Fentanyl Citrate Transdermal Patch - Price Per Unit By Dose (US$), February'2025
• Figure 9-8: Butrans - FDA Approval Year By Dose
• Figure 9-9: US - Butrans FDA Approval & 1st Generic Approval Year
• Figure 9-10: Butrans - Approval Year By Region
• Figure 9-11: Butrans - Price Per Unit & Supply In US (US$), March'2025
• Figure 9-12: Butrans - Initial & Maximum Recommended Dose (mcg/hr)
• Figure 9-13: Butrans - Price Per Unit & Supply In UK (US$), February'2025
• Figure 9-14: Bunov - Initial & Maximum Recommended Dose (mg/hr)
• Figure 9-15: Sevodyne - Price Per Supply (US$), February'2025
• Figure 9-16: Transtec - Price Per Supply In UK (US$), February'2025
• Figure 9-17: Generic Buprenorphine Transdermal Patch - Price Per Unit & Supply In US (USS), March'2025
• Figure 9-18: Zicthoru - Price Per Unit & Supply (US$), February'2025
• Figure 9-19: Zicthoru - Annual Sales (US$), 2021-2024
• Figure 9-20: Branded & Generic Flector Patch - Price Per Unit & Supply In US (US$), March'2025
• Figure 9-21: Licart - Price Per Unit & Supply In US (US$), March'2025
• Figure 9-22: Mohrus - Price Per Supply By Dose (US$), February'2025
• Figure 9-23: Mohrus - Annual Sales (US$), 2020-2024
• Figure 9-24: Versatis - Price Per Supply By Region (US$), February'2025
• Figure 9-25: ZTlido - Price Per Unit & Supply (US$), February'2025
• Figure 9-26: Qutenza - Price Per Unit By Region (US$), February'2025
• Figure 9-27: Salonpas - Price Per Unit & Supply In US (US$), March'2025
• Figure 9-28: Generic Methyl Salicylate Patch - Price Per Unit & Supply In US (US$), March'2025
• Figure 9-29: Tokuhon - Price Per Supply (US$), February'2025
• Figure 9-30: Yakuban Tape - Price Per Supply Of 60mg Tape (US$), February'2025
• Figure 9-31: Yakuban Tape - Price Per Supply Of 20mg Tape (US$), February'2025
• Figure 9-32: TransAct Lat - Price Per Supply By Online Pharmacy (US$), February'2025
• Figure 10-1: Alora - FDA Approval Year By Dose
• Figure 10-2: Alora - Recommended Dose For Treatment Of Vaginal Atrophy & Postmenopausal Osteoporosis (mg/Day Twice In A Week)
• Figure 10-3: Vivelle-Dot - FDA Approval & First Generic Approval Year
• Figure 10-4: Vivelle-Dot - Price Per Unit & Supply In US (US$), March'2025
• Figure 10-5: Vivelle-Dot - Recommended Dose (mg/Day Twice a Week)
• Figure 10-6: Vivelle-Dot - Annual Sales (US$), 2020-2024
• Figure 10-7: Minivelle - FDA Approval Year By Dose
• Figure 10-8: Minivelle - FDA Approval & First Generic Approval Year
• Figure 10-9: US - Minivelle Patent Issue & Expiration Year
• Figure 10-10: Minnivelle - Price Per Unit & Supply In US (US$), March'2025
• Figure 10-11: Minivelle - Recommended Dose By Indication (mg/Day)
• Figure 10-12: Minivelle - Annual Sales (US$), 2020-2024
• Figure 10-13: Climara - FDA Approval Year By Dose
• Figure 10-14: Climara - FDA Approval & First Generic Approval Year
• Figure 10-15: Climara - Price Per Unit & Supply In Canada (US$), February'2025
• Figure 10-16: Menostar - Price Per Unit & Supply In US (US$), March'2025
• Figure 10-17: FemSeven - Price Per Unit & Supply (Euro/US$), February'2025
• Figure 10-18: FemSeven - Initial & Increased Dosage For Postmenopausal Symptoms (mg/hr)
• Figure 10-19: Estrana - Price Per Supply (US$), February'2025
• Figure 10-20: Estrana - Annual Sales (US$), 2020-2024
• Figure 10-21: Generic Estradiol Transdermal Patch - Price Per Unit & Supply Of Twice Weekly Patch In US (US$), March'2025
• Figure 10-22: Generic Estradiol Transdermal Patch - Price Per Unit & Supply Of Weekly Patch In US (US$), March'2025
• Figure 10-23: Androderm - Price Per Unit & Supply In US (US$), March'2025
• Figure 10-24: Androderm - Recommended Initial & Maintainence Dose For Treatment of Hypogonadism (mg/day)
• Figure 10-25: Xulane - FDA Approval & First Generic Approval Year
• Figure 10-26: Ortho Evara - FDA & EMA Approval Year
• Figure 10-27: Xulane & Zafemy - Price Per Unit & Supply In US (US$), March'2025
• Figure 10-28: Ethinyl Estradiol/Norelgestromin Patch - Recommended Schedule for Achieving Birth Control Effect (Days)
• Figure 10-29: Evra - Price Per Unit & Supply In UK (US$), February'2025
• Figure 10-30: CombiPatch - Price Per Unit & Supply In US (US$), March'2025
• Figure 10-31: CombiPatch - Price Per Unit & Supply In Canada (US$), February'2025
• Figure 10-32: CombiPatch - Annual Sales (US$), 2020-2024
• Figure 10-33: Estradiol/Levonorgestrel - Approval Year By Region
• Figure 10-34: Climara Pro - Price Per Unit & Supply In US (US$), March'2025
• Figure 10-35: FemSeven Conti - Price Per Unit & Supply In UK (US$), February'2025
• Figure 10-36: US - Twirla Patent Issue & Expiration Year
• Figure 10-37: Twirla - Price Per Unit & Supply (US$), March'2025
• Figure 10-38: Twirla - Recommended Schedule For Achieving Birth Control Effect (Days)
• Figure 11-1: Transderm-Scop - FDA Approval & 1st Generic Approval Year
• Figure 11-2: Transderm-Scop - Price Per Unit & Supply (US$), March'2025
• Figure 11-3: Scopolamine - Price Per Unit & Supply (US$), March'2025
• Figure 11-4: Emsam - Price Per Unit & Supply (US$), March'2025
• Figure 11-5: Daytrana - FDA Approval & Patent Exclusivity Year
• Figure 11-6: US - Daytrana Patent Issue & Expiration Year
• Figure 11-7: Daytrana - Price Per Unit & Supply (US$), March'2025
• Figure 11-8: Daytrana - Annual Sales (US$), 2020-2024
• Figure 11-9: Xelstrym - Price Per Unit & Supply (US$), March'2025
• Figure 11-10: Xelstrym - Annual Sales (US$), 2023-2024
• Figure 11-11: Lonasen - Price Per Unit in Japan (US$), February'2025
• Figure 11-12: US - Secuado Patent Issue & Expiration Year
• Figure 11-13: Secuado - Price Per Unit & Supply (US$), March'2025
• Figure 11-14: Secuado - Recommended Initial & Incremented Dose (mg/Day)
• Figure 11-15: Secuado - Annual Sales (US$), 2020-2024
• Figure 11-16: Exelon - Approval Year By Region
• Figure 11-17: US - Exelon FDA Approval Year & 1st Generic Approval Year
• Figure 11-18: Exelon - Price Per Unit & Supply In US (US$), March'2025
• Figure 11-19: Generic Rivastigmine Patch - Price Per Unit & Supply (US$), March'2025
• Figure 11-20: Neupro - Approval Year By Region
• Figure 11-21: US - Neupro Approval Year By Indication
• Figure 11-22: Neupro - Patent Issue & Expiration Year
• Figure 11-23: Neupro - Price Per Unit & Supply (US$), March'2025
• Figure 11-24: Neupro - Initial & Maximum Recommended Dose for Early Stage Parkinson (mg/day)
• Figure 11-25: Neupro - Initial & Maximum Recommended Dose for Late Stage Parkinson (mg/day)
• Figure 11-26: Neupro - Initial & Maximum Recommended Dose for Restless Leg Syndrome (mg/day)
• Figure 11-27: Global - Neupro Sales (US$ Million), 2020-2024
• Figure 11-28: Haruropi Tape Patch - Price Per Unit In Japan (US$), February'2025
• Figure 11-29: Haruropi Tape - Initial & Maximum Recommended Dose (mg/day)
• Figure 11-30: Haruropi - Annual Sales (US$), 2020-2024
• Figure 11-31: Adlarity - Price Per Unit & Supply In US (US$), February'2025
• Figure 12-1: Nicotine Transdermal Patch - Approval Year By Region
• Figure 12-2: Nicoderm CQ - Price Per Unit & Supply (US$), March'2025
• Figure 12-3: Generic Nicotine Patch - Price Per Unit & Supply Of 7mg/24hr Transdermal Patches (US$), March'2025
• Figure 12-4: Generic Nicotine Patch - Price Per Unit & Supply Of 14mg/24hr Transdermal Patches (US$), March'2025
• Figure 12-5: Generic Nicotine Patch - Price Per Unit & Supply Of 21mg/24hr Transdermal Patches (US$), March'2025
• Figure 12-6: Nicoderm CQ - Recommended Dose & Treatment Schedule For Patients with Consumption More Than 10 Cigarette/Days (mg/day)
• Figure 12-7: Oxybutynin Transdermal Patch - Approval Year By Region
• Figure 12-8: Oxytrol - Price Per Unit & Supply In US (US$), March'2025
• Figure 12-9: Kentera - Price Per Unit & Supply In UK (US$), February'2025
• Figure 12-10: Sancuso - Approval Year By Region
• Figure 12-11: US - Sancuso Patent Issue & Expiration Year
• Figure 12-12: Allesaga - Price Per Unit By Dose (US$), February'2025
• Figure 12-13: Allesaga - Initial & Maximum Recommended Dose (mg/hr)
• Figure 12-14: Allesaga - Annual Sales (US$), 2020-2023
• Figure 12-15: Tulo-Touch - Price Per Unit By Dose (US$), February'2025
• Figure 12-16: Hokunalin - Price Per Unit By Dose (US$), February'2025
• Figure 13-1: Global Transdermal Patch Market - Favorable Parameters
• Figure 13-2: Global Transdermal Patch Market - Commercialization Challenges

List of Tables

• Table 2-1: Active v/s Passive Transdermal Patch
• Table 3-1: Transdermal Patches For Various Disease Indications
• Table 9-1: Duragesic - Initial Dose Conversion From Other Opioids
• Table 9-2: Butrans - Initial Dose Calculation Using Previous Opioid (Morphine) Dosage
• Table 11-1: Daytrana - Dose Increment Pattern For Treatment Of ADHD

Global Transdermal Patch Market Opportunity, Patch Dosage, Price & Clinical Trials Insight 2030 Report Highlights & Findings:

• Global Transdermal Patch Market Opportunity: US$ 18 Billion By 2030
• US Currently Dominating Global Transdermal Patch Market: > US$ 4 Billion
• China To Emerge Growing Market For Transdermal Patches By 2030
• Currently More Than 60 Patches Are Approved Globally
• Approved Patches Market Availability, Dosage & Price Analysis
• Global Transdermal Market Insights By Region & Indications
• Comprehensive Insight On Clinical Trials By Company, Indication & Phase
• Competitive Landscape: Insight On Key Companies

The global market for transdermal patches has rapidly transformed into a dynamic and intensely competitive arena, where both emerging players and established firms are continually innovating to address the increasing demands of patients. These patches facilitate a controlled and consistent release of therapeutic agents through the skin, serving a diverse array of medical conditions, including pain management, smoking cessation, hormone replacement therapy, and more. An outstanding example of their success is the nicotine patch, which gained popularity as a smoking cessation aid in the early 2000s. Since then, the spectrum of conditions treated by transdermal patches has broadened considerably, now encompassing treatments for ADHD, hormone deficiencies, and nausea, among others. Although they tend to be pricier than conventional drug delivery methods, transdermal patches are witnessing consistent market growth, propelled by their advantageous safety and efficacy profiles.

An essential element in the ongoing expansion of the global transdermal patch market is the attainment of regulatory approval. Successful validations from regulatory authorities are crucial in affirming the credibility of transdermal patches as a viable drug delivery system. For example, Zydus Lifesciences received the final FDA approval for its scopolamine transdermal system aimed at treating nausea and vomiting in August 2024. Likewise, Sino Biopharmaceutical obtained NMPA approval in September 2024 for its rivastigmine transdermal patch, intended for the treatment of mild to moderate Alzheimer's disease. This approval represents a significant achievement, as it is the first domestically manufactured rivastigmine patch authorized for sale in China, emphasizing the increasing acceptance of transdermal patches on a global scale.

The commercial viability of transdermal patches is further enhanced significantly by ongoing innovations in drug delivery systems. For instance, Anodyne Nanotech's HeroPatch(TM) platform has demonstrated encouraging preclinical outcomes in the transdermal administration of GLP-1 receptor agonists, including semaglutide, achieving over 50% bioavailability. This advancement has the potential to transform the management of chronic diseases such as diabetes by providing a needle-free, weekly alternative to traditional injections. Clinical trials for the HeroPatch(TM) are anticipated to commence in 2025, reinforcing the role of transdermal patches as a pivotal element in drug delivery technology.

In another momentous development, researchers at Central South University in China have created a long-acting transdermal delivery system for Guanfacine, a non-stimulant medication for ADHD. This patch is designed to enhance drug release and ensure skin safety, with the capability of supporting treatment cycles lasting up to three days, thus offering a more convenient and patient-centric solution. Furthermore, Biotts, a Polish company specializing in drug delivery, is developing an insulin transdermal patch utilizing its MTC-Y carrier technology. This innovation allows for insulin delivery over a period of up to five days, providing a stable and extended alternative to the daily injections typically required by individuals with type 1 diabetes. Positive results from animal studies have been reported, and Biotts aims to begin human trials by 2027, which could significantly improve diabetes management for countless patients.

At present, there are multiple transdermal patches undergoing clinical trials, highlighting the significant potential of this method for drug delivery. These patches are being investigated across a growing array of therapeutic areas, such as chronic pain management, diabetes treatment, and even vaccination. With nearly 70 transdermal patches already receiving global approval, the market's growth trajectory appears strong, driven by technological advancements and an expanding spectrum of treatable conditions via transdermal means. Although challenges remain, including skin irritation and limitations in delivering higher drug dosages through a single patch, researchers are making progress in addressing these issues. The outlook for transdermal patches is promising, with ongoing enhancements in drug formulation, patch design, and patient adherence anticipated to further propel market growth.

In conclusion, transdermal patches are on the verge of becoming a widely accepted drug delivery method, providing considerable advantages in terms of patient convenience, reliable therapeutic delivery, and minimized side effects. As the market continues to grow, the clinical and commercial success of transdermal patches is expected to significantly influence the global pharmaceutical landscape, offering patients and healthcare providers more effective, less invasive, and more user-friendly alternatives to conventional drug delivery systems.

Table of Contents

1. Introduction To Transdermal Patch

• 1.1 Overview Of Transdermal Patch
• 1.2 Relevance Of Transdermal Patch

2. Transdermal Patches Classification

• 2.1 Single/ Multiple Layer Drug In Adhesive
• 2.2 Reservoir Transdermal Patches
• 2.3 Matrix Based Transdermal Patches
• 2.4 Vapor Patch
• 2.5 Active & Passive Patch

3. Mechanism Of Transdermal Patch Drug Delivery

• 3.1 Properties Of Transdermal Therapeutics
• 3.2 Components Of Transdermal Patch
• 3.3 Mechanism Of Motion Sickness, Nicotine & Female Contraceptive Transdermal

Patch

• 3.4 Transdermal Patch v/s Traditional Drug Delivery Methods

4. Global Transdermal Patch Market Outlook

• 4.1 Current Market Scenario
• 4.2 Future Market Opportunity

5. Global Transdermal Patch Market Trends By Region

• 5.1 US
• 5.2 Europe
• 5.3 China
• 5.4 Japan
• 5.5 South Korea
• 5.6 UK

6. Global Patch Clinical Pipeline By Company, Indication & Phase

• 6.1 Research
• 6.2 Preclinical
• 6.3 Phase-I
• 6.4 Phase-I/II
• 6.5 Phase-II
• 6.6 Phase-III
• 6.7 Preregistration
• 6.8 Registered

7. Global Marketed Transdermal Patch Clinical Insight

8. Transdermal Patches For Cardiovascular Diseases - Market Availability, Dosage & Price Analysis

• 8.1 Nitroglycerin Transdermal Patch
  • 8.1.1 Nitro-Dur
  • 8.1.2 Nitro TD Patch A
  • 8.1.3 Generic Nitroglycerin Transdermal Patch
• 8.2 Clonidine Transdermal Patch
  • 8.2.1 Catapres-TTS
  • 8.2.2 Generic Clonidine Transdermal Patch
• 8.3 Bisoprolol Transdermal Patch (Bisono)

9. Transdermal Analgesic Patches - Market Availability, Dosage & Price Analysis

• 9.1 Fentanyl Transdermal Patch
  • 9.1.1 Duragesic/Durogesic
  • 9.1.2 Durotep MT
  • 9.1.3 OneDuro
  • 9.1.4 Generic Fentanyl Transdermal Patch
  • 9.1.5 Fentos
  • 9.1.6 Fentadur
  • 9.1.7 Generic Fentanyl Citrate Transdermal Patch
• 9.2 Buprenorphine Transdermal Patch
  • 9.2.1 Butrans
  • 9.2.2 Bunov
  • 9.2.3 Sevodyne
  • 9.2.4 Transtec
  • 9.2.5 Generic Buprenorphine Transdermal Patch
• 9.3 Diclofenac Transdermal Patch
  • 9.3.1 Zicthoru
  • 9.3.2 Flector
  • 9.3.3 Licart
• 9.4 Ketoprofen Transdermal Patch (Mohrus)
• 9.5 Lidocaine Transdermal Patch
  • 9.5.1 Versatis
  • 9.5.2 ZTlido
  • 9.5.3 Penles
  • 9.5.4 Rapydan
• 9.6 Capsaicin Transdermal Patch (Qutenza)
• 9.7 Methyl Salicate Transdermal Patch
  • 9.7.1 Salonpas
  • 9.7.2 Tokuhon
• 9.8 Glycol Salicylate Transdermal Patch (Tokuhon E)
• 9.9 Flurbiprofen Transdermal Patch
  • 9.9.1 Loqoa
  • 9.9.2 Yakuban Tape
  • 9.9.3 Transact Lat

10. Transdermal Patch In Hormonal Therapy - Market Availability, Dosage & Price Analysis

• 10.1 Estradiol Transdermal Patch
  • 10.1.1 Alora
  • 10.1.2 Vivelle-Dot
  • 10.1.3 Minivelle
  • 10.1.4 Climara
  • 10.1.5 Menostar
  • 10.1.6 FemSeven
  • 10.1.7 Estrana
  • 10.1.8 Generic Estradiol Transdermal Patch
• 10.2 Testosterone Transdermal Patch (Androderm)
• 10.3 Estradiol/ Norethisterone Transdermal Patch
  • 10.3.1 Xulane/Ortho Evra
  • 10.3.2 Combipatch
  • 10.3.3 Menoaid Combi Patch
  • 10.3.4 Evorel Conti
• 10.4 Estradiol/Levonorgestrel Transdermal Patch
• 10.5 Ethinyl Estradiol/Levonorgestrel (Twirla)
• 10.6 Ethinyl Estradiol/Gestodene (Apleek)

11. Transdermal Patches For Neurological Disorders - Market Availability, Dosage & Price Analysis

• 11.1 Scopolamine Transdermal Patch (Transderm-Scop)
• 11.2 Selegiline Transdermal Patch (Emsam)
• 11.3 Methylphenidate Transdermal Patch (Daytrana)
• 11.4 Dextroamphetamine Transdermal Patch (Xelstrym)
• 11.5 Blonanserin Transdermal Patch (Lonasen)
• 11.6 Asenapine Transdermal Patch (Secuado)
• 11.7 Rivastigmine Transdermal Patch
  • 11.7.1 Exelon
  • 11.7.2 Generic Rivastigmine Transdermal Patch
• 11.8 Rotigotine Transdermal Patch (Neupro)
• 11.9 Ropinirole Hydrochloride (Haruropi Tape)
• 11.10 Donepezil Transdermal Patch (Adlarity)

12. Patches For Other Conditions - Market Availability, Dosage & Price Analysis

• 12.1 Nicotine Transdermal Patch (Nicoderm CQ/ Nicotinell TTS)
• 12.2 Oxybutynin Transdermal Patch (Oxytrol/Kentera)
• 12.3 Granisetron Transdermal Patch (Sancuso)
• 12.4 Emedastine Transdermal Patch (Allesaga)
• 12.5 Fibrin Sealant Transdermal Patch
  • 12.5.1 Evarrest
  • 12.5.2 TachoSil
• 12.6 5-Aminolevulinic Acid Transdermal Patch (Alacare)
• 12.7 Tulobuterol Transdermal Patch
  • 12.7.1 Tulo-Touch
  • 12.7.2 Hokunarin

13. Global Transdermal Patch Market Dynamics

• 13.1 Favorable Market Parameters
• 13.2 Commercialization Challenges

14. Competitive Landscape

• 14.1 AbbVie
• 14.2 Bayer HealthCare Pharmaceuticals
• 14.3 Corium International
• 14.4 Endo Pharmaceuticals
• 14.5 Hisamitsu Pharmaceutical
• 14.6 Luye Pharma
• 14.7 Noven Pharmaceuticals
• 14.8 Novartis
• 14.9 Purdue Pharma
• 14.10 Scilex Pharmaceuticals
• 14.11 Searchlight Pharma
• 14.12 Somerset Pharmaceuticals
• 14.13 Teikoku Seiyaku
• 14.14 Teva Pharmaceuticals
• 14.15 UCB
• 14.16 DURECT Corporation
• 14.17 Senju Pharmaceutical